News
Tirzepatide use vs placebo was associated with slower decline in eGFR among patients with prediabetes and obesity or overweight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results